Head-to-head · Cost-Efficiency Index
VigorMeds vs Evernow
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
VigorMeds
Cost-first shoppers who want a needle-free sublingual GLP-1 that's meaningfully cheaper than the injectable version, from named physicians.
Visit VigorMedsEvernow
Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Visit EvernowThe verdict
VigorMeds takes it, leading the Cost-Efficiency Index 50 to 49. VigorMeds (Vigormeds LLC) is a provider-guided telehealth platform selling both injectable and needle-free sublingual compounded semaglutide ($139-$199/mo) and tirzepatide ($159-$299/mo). Evernow still earns a C — Cost-first shoppers who want women 40+ wanting GLP-1 prescribing integrated with menopause/hormone care, ideally with insurance.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs VigorMeds.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | VigorMeds | Evernow |
|---|---|---|
| Cost-Efficiency Index | 50/100 | 49/100 |
| Semaglutide / mo | $199/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide / mo | $299/mo (starting dose, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | — |
| Tirzepatide / yr (modeled) | $3,588 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #416 | #421 |
VigorMeds
50/100Where the value is
- Both injectable and needle-free sublingual forms of semaglutide ($139/mo) and tirzepatide ($159/mo) — the sublingual tier is $60-$140/mo cheaper than the injectable tier
- Named, credentialed clinicians reviewing cases: Dr. Anthony Kane MD, Dr. Claudia Mondragon MD, Dr. Kevin Kargman MD, Stephanie Kowatch MSN FNP-C
- 'Pay upon medical approval' — no charge until a provider signs off on treatment, plus a 30-day satisfaction guarantee
The tradeoffs
- The dedicated 'States We Serve' page names zero actual states in its crawlable content — only vague buckets like 'Coming soon' and 'Room to grow'
- The FIRST100 promo code discounts whichever tier is chosen by $100 for the first month, so the price shown at signup is not the ongoing rate
Evernow
49/100Where the value is
- Confirmed genuine GLP-1 prescribing (not hormone-therapy-only, despite the brand's menopause focus)
- Only prescribes FDA-approved branded medications, no compounded-drug quality uncertainty
- Available in all 50 states plus D.C.
The tradeoffs
- No cash-pay price published anywhere -- cost is insurance-dependent and opaque to uninsured shoppers
- No compounded option for patients priced out of branded GLP-1s
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.